OBJECTIVE: Our objective was to systematically analyze the evidence for an association between serum level long chain omega-3 polyunsaturated fatty acid (n-3 PUFA) and prostate cancer risk from human epidemiological studies. STUDY PROCEDURES: We searched biomedical literature databases up to November 2011 and included epidemiological studies with description of long chain n-3 PUFA and incidence of prostate cancer in humans. Critical appraisal was done by two independent reviewers. Data were pooled using the general variance-based method with random-effects model; effect estimates were expressed as risk ratio with 95% confidence interval (CI). Heterogeneity was assessed by Chi(2) and quantified by I(2), publication bias was also determined. RESULTS: In total, 12 studies were included. Significant negative association was noted between high serum level of n-3 PUFA doc-osapentaenoic acid (DPA) and total prostate cancer risk (RR:0.756; 95% CI 0.599, 0.955; p = 0.019). Likewise, a positive association between high blood level of fish oil contents, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and high-grade prostate tumour incidence (RR:1.381; 95% CI 1.050, 1.817; p = 0.021) was noted; however, this finding was evident only after adjustment was done on interstudy variability through the removal of a lower quality study from the pool. CONCLUSIONS: High serum levels of long chain n-3 PUFA DPA is associated with reduced total prostate cancer risk. While high blood level of EPA and DHA is possibly associated with increased high-grade prostate tumour risk.
OBJECTIVE: Our objective was to systematically analyze the evidence for an association between serum level long chainomega-3 polyunsaturated fatty acid (n-3 PUFA) and prostate cancer risk from human epidemiological studies. STUDY PROCEDURES: We searched biomedical literature databases up to November 2011 and included epidemiological studies with description of long chain n-3 PUFA and incidence of prostate cancer in humans. Critical appraisal was done by two independent reviewers. Data were pooled using the general variance-based method with random-effects model; effect estimates were expressed as risk ratio with 95% confidence interval (CI). Heterogeneity was assessed by Chi(2) and quantified by I(2), publication bias was also determined. RESULTS: In total, 12 studies were included. Significant negative association was noted between high serum level of n-3 PUFAdoc-osapentaenoic acid (DPA) and total prostate cancer risk (RR:0.756; 95% CI 0.599, 0.955; p = 0.019). Likewise, a positive association between high blood level of fish oil contents, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and high-grade prostate tumour incidence (RR:1.381; 95% CI 1.050, 1.817; p = 0.021) was noted; however, this finding was evident only after adjustment was done on interstudy variability through the removal of a lower quality study from the pool. CONCLUSIONS: High serum levels of long chain n-3 PUFADPA is associated with reduced total prostate cancer risk. While high blood level of EPA and DHA is possibly associated with increased high-grade prostate tumour risk.
Authors: June M Chan; Vivian Weinberg; Mark J Magbanua; Eduardo Sosa; Jeffry Simko; Katsuto Shinohara; Scot Federman; Mike Mattie; Millie Hughes-Fulford; Christopher Haqq; Peter R Carroll Journal: Cancer Causes Control Date: 2010-11-20 Impact factor: 2.506
Authors: Tiina Solakivi; Olli Jaakkola; Anne Kalela; Mari Pispa; Anne Salomäki; Terho Lehtimäki; Matti Höyhtyä; Hannu Jokela; Seppo T Nikkari Journal: Lipids Health Dis Date: 2005-04-13 Impact factor: 3.876
Authors: Francesca L Crowe; Naomi E Allen; Paul N Appleby; Kim Overvad; Inge V Aardestrup; Nina F Johnsen; Anne Tjønneland; Jakob Linseisen; Rudolf Kaaks; Heiner Boeing; Janine Kröger; Antonia Trichopoulou; Assimina Zavitsanou; Dimitrios Trichopoulos; Carlotta Sacerdote; Domenico Palli; Rosario Tumino; Claudia Agnoli; Lambertus A Kiemeney; H Bas Bueno-de-Mesquita; María-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; José R Quirós; Maria-José Sánchez; Carlos A González; Pär Stattin; Göran Hallmans; Sheila Bingham; Kay-Tee Khaw; Sabina Rinaldi; Nadia Slimani; Mazda Jenab; Elio Riboli; Timothy J Key Journal: Am J Clin Nutr Date: 2008-11 Impact factor: 7.045
Authors: Fabio J Pacheco; Frankis G Almaguel; Whitney Evans; Leslimar Rios-Colon; Valery Filippov; Lai S Leoh; Elizabeth Rook-Arena; Melanie Mediavilla-Varela; Marino De Leon; Carlos A Casiano Journal: Inflamm Res Date: 2014-08-06 Impact factor: 4.575
Authors: Lauren A Wise; Rose G Radin; Shiriki K Kumanyika; Edward A Ruiz-Narváez; Julie R Palmer; Lynn Rosenberg Journal: Am J Clin Nutr Date: 2014-03-05 Impact factor: 7.045
Authors: Jenifer I Fenton; Norman G Hord; Sanjoy Ghosh; Eric A Gurzell Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2013-09-30 Impact factor: 4.006
Authors: Jeffrey L Cummings; Richard S Isaacson; Frederick A Schmitt; Drew M Velting Journal: Ann Clin Transl Neurol Date: 2015-01-23 Impact factor: 4.511
Authors: Dominik D Alexander; Julie K Bassett; Douglas L Weed; Erin Cernkovich Barrett; Heather Watson; William Harris Journal: Nutr Cancer Date: 2015-03-31 Impact factor: 2.900
Authors: Andrea Dueregger; Isabel Heidegger; Philipp Ofer; Bernhard Perktold; Reinhold Ramoner; Helmut Klocker; Iris E Eder Journal: Nutrients Date: 2014-10-21 Impact factor: 5.717